Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer - Reply

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF UROLOGY | 2001年 / 165卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1467 / 1467
页数：1
相关论文
共 50 条
  • [31] Comparison of urinary MNP22™ and BTA-stat™ with voided urinary cytology and cystoscopy in the detection and follow-up of bladder cancer:: Can urinary NMP22™ and BTA-stat™-test replace cystoscopy?
    Poulakis, V
    Witzsch, U
    Kollias, A
    Wolfram, M
    Becht, E
    Altmannsberger, HM
    AKTUELLE UROLOGIE, 1999, 30 (07) : 466 - 475
  • [32] Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients
    Takashi M.
    Schenck U.
    Kissel K.
    Leyh H.
    Treiber U.
    International Urology and Nephrology, 1999, 31 (2) : 189 - 196
  • [33] Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors
    Eissa, S
    Swellam, M
    Sadek, M
    Mourad, MS
    Ahmady, OE
    Khalifa, A
    JOURNAL OF UROLOGY, 2002, 168 (02): : 465 - 469
  • [34] Comparison of sensitivity and specificity between single voided urine and cystoscopically collected urine in the detection of bladder cancer utilizing urinary cytology, telomerase, NMP22 and BTA Stat.
    Bhuiyan, AKM
    Ramakumar, S
    Roberts, SG
    Blute, ML
    O'Kane, DJ
    CLINICAL CHEMISTRY, 1998, 44 : A162 - A162
  • [35] Clinical evaluation of soluble cytokeratin 19 fragments (cyfra 21-1) in serum and urine of patients with bladder cancer
    Senga, Y
    Kimura, G
    Hattori, O
    Yoshida, K
    UROLOGY, 1996, 48 (05) : 703 - 710
  • [36] Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy
    Andreadis, C
    Touloupidis, S
    Galaktidou, G
    Kortsaris, AH
    Boutis, A
    Mouratidou, D
    JOURNAL OF UROLOGY, 2005, 174 (05): : 1771 - 1775
  • [37] Low utility of CYFRA 21-1 serum levels for diagnosis and follow-up in bladder cancer patients
    Fatela-Cantillo, D
    Fernández-Suárez, A
    Menéndez, V
    Galán, JA
    Filella, X
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2005, 19 (04) : 167 - 171
  • [38] BTA stat®, Alere NMP22® BladderChek®, UBC® rapid test, and uromonitor® in comparison to cytology as tumor marker for urinary bladder cancer: New results of a german multicentre-study
    Ecke, T. H.
    Meisl, C.
    Hofbauer, S.
    Labonte, F.
    Schlomm, T.
    Friedersdorff, F.
    Goessl, A.
    Barski, D.
    Otto, T.
    Grunewald, C.
    Niegisch, G.
    Hennig, M.
    Kramer, M.
    Koch, S.
    Hallmann, S.
    EUROPEAN UROLOGY, 2022, 81 : S115 - S115
  • [39] Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy - Comment
    Konety, B
    JOURNAL OF UROLOGY, 2005, 174 (05): : 1775 - 1776
  • [40] ASSESSING THE CLINICAL BENEFIT OF NMP22 IN THE SURVEIL LANCE OF PATIENTS WITH NON MUSCLE INVASIVE BLADDER CANCER AND NEGATIVE CYTOLOGY A DECISION CURVE ANAL YSIS
    Shariat, Shahrokh F.
    Meryn, Siegfried
    Lee, Richard
    Marberger, Michael J.
    Scherr, Douglas S.
    Savage, Caroline
    Karakiewicz, Pierre I.
    Vickers, Andrew J.
    JOURNAL OF MENS HEALTH, 2010, 7 (03) : 341 - 341
12345